Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NASDAQ:FRMM NASDAQ:GANX NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.66$0.82$0.49▼$6.19$61.74M3.4271,833 shs40,742 shsFRMMForum Markets$5.35$4.19$1.76▼$174.60$77.79M1.45304,688 shs300,034 shsGANXGain Therapeutics$1.68$1.84$1.41▼$4.34$71.65M0.16706,982 shs482,863 shsTPSTTempest Therapeutics$1.26$1.74$1.23▼$12.23$18.66M-1.8595,980 shs37,770 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology0.00%-14.87%-31.07%-17.61%-54.83%FRMMForum Markets0.00%+5.11%+44.59%+534,999,900.00%+534,999,900.00%GANXGain Therapeutics0.00%-1.18%-4.00%-33.33%-2.89%TPSTTempest Therapeutics0.00%-0.79%-31.15%-42.99%-80.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.66$0.82$0.49▼$6.19$61.74M3.4271,833 shs40,742 shsFRMMForum Markets$5.35$4.19$1.76▼$174.60$77.79M1.45304,688 shs300,034 shsGANXGain Therapeutics$1.68$1.84$1.41▼$4.34$71.65M0.16706,982 shs482,863 shsTPSTTempest Therapeutics$1.26$1.74$1.23▼$12.23$18.66M-1.8595,980 shs37,770 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology0.00%-14.87%-31.07%-17.61%-54.83%FRMMForum Markets0.00%+5.11%+44.59%+534,999,900.00%+534,999,900.00%GANXGain Therapeutics0.00%-1.18%-4.00%-33.33%-2.89%TPSTTempest Therapeutics0.00%-0.79%-31.15%-42.99%-80.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.33Hold$6.00803.61% UpsideFRMMForum Markets 2.50Moderate Buy$10.0086.92% UpsideGANXGain Therapeutics 2.67Moderate Buy$8.50405.95% UpsideTPSTTempest Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest TPST, FRMM, CTOR, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026FRMMForum Markets Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.005/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026FRMMForum Markets Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.005/11/2026FRMMForum Markets Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/10/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSpeculative Buy$5.004/2/2026FRMMForum Markets Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.54 per shareN/AFRMMForum Markets$6.55M11.88N/AN/A$12.59 per share0.42GANXGain Therapeutics$50K1,433.04N/AN/A$0.48 per share3.50TPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)FRMMForum Markets-$450.52M-$36.07N/A33.44N/AN/A-242.09%-135.46%N/AGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)TPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)Latest TPST, FRMM, CTOR, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A3/31/2026Q4 2025FRMMForum MarketsN/A-$12.14N/A-$12.24N/A$2.44 million3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/A3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.500.12FRMMForum Markets0.156.196.19GANXGain Therapeutics0.024.694.69TPSTTempest TherapeuticsN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%FRMMForum Markets4.07%GANXGain Therapeutics11.97%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology9.80%FRMMForum Markets15.10%GANXGain Therapeutics4.15%TPSTTempest Therapeutics36.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A92.98 million83.87 millionN/AFRMMForum Markets714.54 million12.35 millionN/AGANXGain Therapeutics2042.65 million40.88 millionOptionableTPSTTempest Therapeutics2014.81 million9.43 millionNo DataTPST, FRMM, CTOR, and GANX HeadlinesRecent News About These CompaniesTempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | quiverquant.comQTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | globenewswire.comTempest Therapeutics Announces Resignation of Board DirectorMay 29, 2026 | tipranks.comTempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term WarrantsMay 29, 2026 | quiverquant.comQTempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsMay 29, 2026 | globenewswire.comTempest Therapeutics Announces Multiple Board Director ResignationsMay 22, 2026 | tipranks.comTempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | finanznachrichten.deTempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6, 2026 | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comNew Strong Buy Stocks for April 10thApril 10, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comTempest Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comTempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 SharesMarch 26, 2026 | insidertrades.comTempest Therapeutics Announces Up To $6 Million Private PlacementMarch 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 12, 2026 | finanznachrichten.deTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 26, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchBy Leo Miller | May 26, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026TPST, FRMM, CTOR, and GANX Company DescriptionsCitius Oncology NASDAQ:CTOR$0.66 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.66 0.00 (0.00%) As of 06/12/2026 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Forum Markets NASDAQ:FRMM$5.35 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$5.30 -0.05 (-0.95%) As of 06/12/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.Gain Therapeutics NASDAQ:GANX$1.68 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.72 +0.04 (+2.32%) As of 06/12/2026 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Tempest Therapeutics NASDAQ:TPST$1.26 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.26 +0.00 (+0.40%) As of 06/12/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
